inclusion criteria: 1. male or female healthy volunteer ≥20 and \<50 years of age 2. subject free of ongoing acute diseases or serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. new york heart association grade iii or iv), hepatic (e.g. child-pugh class c), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigator's opinion could interfere with the results of the trial or adversely affect the safety of the subject 3. female subject must be: * either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal; * or, if of childbearing potential, must be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following last injection of study vaccines. acceptable forms include: * implanted hormonal methods of contraception or placement of an intrauterine device (iud) or intrauterine system (ius) * established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) withspermicidal foam/gel/film/cream/suppository * have a negative pregnancy test 4. subject is willing and able to comply with all required study visits and follow-up required by this protocol 5. subject has no overseas travel within 14 days of screening and will not have any throughout the study period 6. subject must provide written informed consent or the subject's legal representative must understand and consent to the procedure

inclusion criteria: 1. male or female healthy volunteer ≥20 and \<50 years of age 2. subject free of ongoing acute diseases or serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. new york heart association grade iii or iv), hepatic (e.g. child-pugh class c), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigator's opinion could interfere with the results of the trial or adversely affect the safety of the subject 3. female subject must be: * either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal; * or, if of childbearing potential, must be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following last injection of study vaccines. acceptable forms include: * implanted hormonal methods of contraception or placement of an intrauterine device (iud) or intrauterine system (ius) * established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) withspermicidal foam/gel/film/cream/suppository * have a negative pregnancy test 4. subject is willing and able to comply with all required study visits and follow-up required by this protocol 5. subject has no overseas travel within 14 days of screening and will not have any throughout the study period 6. subject must provide written informed consent or the subject's legal representative must understand and consent to the procedure

inclusion criteria: male or female healthy volunteer ≥20 and <50 years of age subject free of ongoing acute diseases or serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. new york heart association grade iii or iv), hepatic (e.g. child-pugh class c), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigator's opinion could interfere with the results of the trial or adversely affect the safety of the subject female subject must be: either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal; or, if of childbearing potential, must be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following last injection of study vaccines. acceptable forms include: implanted hormonal methods of contraception or placement of an intrauterine device (iud) or intrauterine system (ius) established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) withspermicidal foam/gel/film/cream/suppository have a negative pregnancy test subject is willing and able to comply with all required study visits and follow-up required by this protocol subject has no overseas travel within 14 days of screening and will not have any throughout the study period subject must provide written informed consent or the subject's legal representative must understand and consent to the procedure

inclusion criteria: male or female healthy volunteer ≥20 and <50 years of age subject free of ongoing acute diseases or serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. new york heart association grade iii or iv), hepatic (e.g. child-pugh class c), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigator's opinion could interfere with the results of the trial or adversely affect the safety of the subject female subject must be: either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal; or, if of childbearing potential, must be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following last injection of study vaccines. acceptable forms include: implanted hormonal methods of contraception or placement of an intrauterine device (iud) or intrauterine system (ius) established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) withspermicidal foam/gel/film/cream/suppository have a negative pregnancy test subject is willing and able to comply with all required study visits and follow-up required by this protocol subject has no overseas travel within 14 days of screening and will not have any throughout the study period subject must provide written informed consent or the subject's legal representative must understand and consent to the procedure

inclusion criteria: 1. male or female healthy volunteer ≥20 and <50 years of age 2. subject free of ongoing acute diseases or serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. new york heart association grade iii or iv), hepatic (e.g. child-pugh class c), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigator's opinion could interfere with the results of the trial or adversely affect the safety of the subject 3. female subject must be: - either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal; - or, if of childbearing potential, must be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following last injection of study vaccines. acceptable forms include: - implanted hormonal methods of contraception or placement of an intrauterine device (iud) or intrauterine system (ius) - established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) withspermicidal foam/gel/film/cream/suppository - have a negative pregnancy test 4. subject is willing and able to comply with all required study visits and follow-up required by this protocol 5. subject has no overseas travel within 14 days of screening and will not have any throughout the study period 6. subject must provide written informed consent or the subject's legal representative must understand and consent to the procedure

inclusion criteria: 1. male or female healthy volunteer ≥20 and <50 years of age 2. subject free of ongoing acute diseases or serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. new york heart association grade iii or iv), hepatic (e.g. child-pugh class c), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigator's opinion could interfere with the results of the trial or adversely affect the safety of the subject 3. female subject must be: - either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal; - or, if of childbearing potential, must be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following last injection of study vaccines. acceptable forms include: - implanted hormonal methods of contraception or placement of an intrauterine device (iud) or intrauterine system (ius) - established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) withspermicidal foam/gel/film/cream/suppository - have a negative pregnancy test 4. subject is willing and able to comply with all required study visits and follow-up required by this protocol 5. subject has no overseas travel within 14 days of screening and will not have any throughout the study period 6. subject must provide written informed consent or the subject's legal representative must understand and consent to the procedure